Annual Drug Patent Expirations for RINVOQ
Rinvoq is a drug marketed by Abbvie and is included in one NDA. It is available from one supplier. There are twenty-six patents protecting this drug.
Drug patent litigation for RINVOQ.
This drug has one hundred and seventy-three patent family members in forty-one countries.
The generic ingredient in RINVOQ is upadacitinib. One supplier is listed for this compound. Additional details are available on the upadacitinib profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
